Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOX1 | Q9Y5S8 | 2/20 | 0.58 |
| ▸ | CYBB | P04839 | 1/20 | 0.58 |
| ▸ | NOX3 | Q9HBY0 | 1/20 | 0.58 |
| ▸ | NOX4 | Q9NPH5 | 1/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.50 |
| ▸ | HPGD | P15428 | 3/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.50 |
| ▸ | MAPT | P10636 | 2/20 | 0.50 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | AR | P10275 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 3/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.40 |
| ▸ | GAA | P10253 | 2/20 | 0.40 |
| ▸ | MRGPRX4 | Q96LA9 | 3/20 | 0.40 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.39 |
| ▸ | JUN | P05412 | 1/20 | 0.39 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.39 |
| ▸ | RELA | Q04206 | 1/20 | 0.39 |
| ▸ | TAS2R14 | Q9NYV8 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Flutiazin SCHEMBL29394002 | 1.00 | NOX1 (0.58) | NOX1CYBBNOX3NOX4ALDH1A1 | |
| Flutiazin SCHEMBL11811863 | 0.99 | NOX1 (0.57) | NOX1CYBBNOX3NOX4ALDH1A1 | |
| Flutiazin SCHEMBL11818117 | 0.93 | NOX1 (0.51) | NOX1CYBBNOX3NOX4ALDH1A1 | |
| SCHEMBL11823962 | 0.91 | NOX1 (0.49) | NOX1CYBBNOX3NOX4ALDH1A1 | |
| SCHEMBL11811857 | 0.89 | NOX1 (0.57) | NOX1CYBBNOX3NOX4ALDH1A1 | |
| SCHEMBL11808295 | 0.83 | NOX1 (0.44) | NOX1CYBBNOX3NOX4ALDH1A1 | |
| SCHEMBL11818111 | 0.83 | NOX1 (0.50) | NOX1CYBBNOX3NOX4ALDH1A1 | |
| Flutiazin SCHEMBL10532803 | 0.81 | CFD (0.44) | NOX1CYBBNOX3NOX4ALDH1A1 | |
| SCHEMBL11818316 | 0.80 | NOX1 (0.55) | NOX1CYBBNOX3NOX4ALDH1A1 | |
| SCHEMBL293434 | 0.79 | ALOX5 (0.54) | NOX1CYBBNOX3NOX4ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 861 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240200072-A1 | Allogeneic Cartilage Regeneration | Tarachon, LLC (US) | 2024-06-20 | — | — | US | claimed |
| EP-3752201-B1 | SUSPENSION OF NANOSCALE, ORGANIC PARTICLES AND PROCESS FOR PRODUCTION THEREOF | UNIV FRIEDRICH ALEXANDER ER (DE) | 2023-11-22 | — | — | EP | claimed |
| EP-3752201-A1 | SUSPENSION OF NANOSCALE, ORGANIC PARTICLES AND PROCESS FOR PRODUCTION THEREOF | Friedrich-Alexander-Universität Erlangen-Nürnberg (DE) | 2020-12-23 | — | — | EP | claimed |
| EP-3691658-A2 | IMMUNOMODULATORY OLIGOSACCHARIDES | The Regents of The University of California (US) | 2020-08-12 | — | — | EP | claimed |
| WO-2019158509-A1 | SUSPENSION OF NANOSCALE, ORGANIC PARTICLES AND PROCESS FOR PRODUCTION THEREOF | Friedrich-Alexander-Universität Erlangen-Nürnberg (DE) | 2019-08-22 | — | — | WO | claimed |
| WO-2019071021-A2 | IMMUNOMODULATORY OLIGOSACCHARIDES | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2019-04-11 | — | — | WO | claimed |
| EP-3351262-A1 | CURAGLUTIDE FOR IN TREATMENT OF PREDIABETES, DIABETES, OBESITY AND METABOLIC DISEASES ASSOCIATED THERETO | Istanbul Universitesi Rektorlugu (TR) | 2018-07-25 | — | — | EP | claimed |
| US-9566349-B2 | Intestinal peptide targeting ligands | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 2017-02-14 | — | — | US | claimed |
| US-20160022820-A1 | TRANSDERMAL DELIVERY SYSTEM | ACRUX DDS PTY LTD. (AU) | 2016-01-28 | — | — | US | claimed |
| US-20150202322-A1 | INTESTINAL PEPTIDE TARGETING LIGANDS | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY | 2015-07-23 | — | — | US | claimed |
| US-7070765-B2 | Delivery of drug esters through an inhalation route | ALEXZA PHARMACEUTICALS, INC. (US) | 2006-07-04 | — | — | US | claimed |
| US-20060100263-A1 | Antipyretic compositions and methods | DOV PHARMACEUTICAL, INC. | 2006-05-11 | — | — | US | claimed |
| WO-2006050520-A2 | ANTIPYRETIC COMPOSITIONS AND METHODS | DOV PHARMACEUTICAL, INC. (US) | 2006-05-11 | — | — | WO | claimed |
| WO-2003099293-A1 | PHARMACOLOGICALLY ACTIVE SALTS | DANMARKS FARMACEUTISKE UNIVERSITET (DK) | 2003-12-04 | — | — | WO | claimed |
| EP-1336602-A1 | Nitrate prodrugs able to release nitric oxide in a controlled and selective way and their use for prevention and treatment of inflammatory, ischemic and proliferative diseases | Scaramuzzino, Giovanni (IT) | 2003-08-20 | — | — | EP | claimed |
| EP-0039051-B1 | MANNICH-BASE HYDROXAMIC ACID PRODRUGS FOR THE IMPROVED BIOAVAILABILITY OF NON-STEROIDAL ANTI-INFLAMMATORY AGENTS, A PROCESS FOR PREPARING AND A PHARMACEUTICAL COMPOSITION CONTAINING THEM | MERCK & CO. INC. (US) | 1985-07-24 | — | — | EP | claimed |
| US-4376767-A | ANTIBIOTICS AND PHARMACEUTICALS | MERCK & CO., INC. (US) | 1983-03-15 | — | — | US | claimed |
| EP-0055870-A1 | Pyridylmethyl esters of selected bio-affecting carboxylic acids, process for preparing and pharmaceutical composition comprising the same | MERCK & CO. INC. (US) | 1982-07-14 | — | — | EP | claimed |
| EP-0051278-A1 | Soft tertiary amine esters of bio-affecting carboxylic acids, processes for preparing and a pharmaceutical composition containing the same | MERCK & CO. INC. (US) | 1982-05-12 | — | — | EP | claimed |
| EP-0039051-A2 | Mannich-base hydroxamic acid prodrugs for the improved bioavailability of non-steroidal anti-inflammatory agents, a process for preparing and a pharmaceutical composition containing them | MERCK & CO. INC. (US) | 1981-11-04 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160022820-A1 | TRANSDERMAL DELIVERY SYSTEM | S100A10, MMP20, TLR6 | NOX1 4355/4885CYBB 3822/4885NOX3 3986/4885 |
| US-20060100263-A1 | Antipyretic compositions and methods | GABRE, HTR5A, TPH2 | NOX1 4745/4885CYBB 3750/4885NOX3 4579/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.